• In the past few days, Option Care Health reported quarterly results that missed analyst revenue expectations, raising questions about the strength of its recent operating performance in home and alternate site infusion therapies.
• This shortfall, especially when contrasted with a peer’s stronger quarter, has sharpened investor focus on how resilient Option Care Health’s growth thesis really is within the evolving at‑home care market.
• Now we’ll examine how the recent revenue miss influences Option Care Health’s investment narrative, particularly its margin improvement and growth assumptions.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Option Care Health Investment Narrative Recap

To own Option Care Health, you have to believe that home and alternate site infusion will remain a preferred, cost efficient setting for complex therapies, and that the company can protect margins despite mix and reimbursement pressures. The recent revenue miss and guidance trim for 2026 signal some strain on that thesis in the near term, but the core question for the next year is whether management can stabilize margins faster than payer and therapy mix risks build.

The most relevant recent development is the April 2026 guidance update, which lowered full year revenue expectations to US$5.675–5.775 billion from the prior US$5.8–6.0 billion. Coming right after a quarter that fell short of analyst revenue estimates and saw the stock sell off, this reset ties directly into the current catalyst: whether Option Care Health can still deliver on its margin and growth assumptions while working through softer revenue trends and industry headwinds.

Yet investors should be aware that if reimbursement pressure, higher verification frictions or a tougher therapy mix persist, then...

Option Care Health's narrative projects $6.8 billion revenue and $298.2 million earnings by 2029. This requires 6.4% yearly revenue growth and a $92.0 million earnings increase from $206.2 million today.

Uncover how Option Care Health's forecasts yield a $28.58 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Before this revenue miss, the most optimistic analysts were assuming revenues of about US$6.9 billion and earnings of roughly US$306 million by 2029, which is far more upbeat than consensus and rests heavily on deeper health plan partnerships and stronger clinic utilization that could now be reassessed.

Explore 2 other fair value estimates on Option Care Health - why the stock might be worth just $24.80!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Option Care Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Option Care Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Option Care Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.